Pneumonic-type lung adenocarcinoma with KRAS G12V mutation and sustained response to Afatinib

Area of Science:

• Oncology
• Radiology
• Genomics

Background:

• Pneumonic-type lung adenocarcinoma (P-ADC) is a rare lung cancer subtype.
• Distinguishing P-ADC from pneumonia on imaging is challenging.
• No targeted therapies exist for KRAS G12V mutations.

Purpose of the Study:

• To report a case of P-ADC with characteristic imaging features.
• To demonstrate the utility of Next-generation sequencing (NGS) for mutation detection.
• To present an effective treatment strategy for KRAS G12V-mutated lung adenocarcinoma.

Main Methods:

• Computed tomography (CT) scans were used to identify imaging features.
• Next-generation sequencing (NGS) detected the KRAS G12V mutation.
• An individualized Afatinib-based treatment regimen was administered.

Main Results:

• The case exhibited typical P-ADC imaging findings including patchy shadows and ground-glass opacities.
• KRAS G12V mutation was confirmed via NGS.
• The patient achieved a sustained response to Afatinib after prior treatments failed.

Conclusions:

• This case illustrates the dynamic imaging characteristics of P-ADC.
• NGS is crucial for identifying actionable mutations like KRAS G12V.
• An individualized Afatinib strategy shows promise for KRAS G12V-mutated lung adenocarcinoma.